Praxis Precision Medicines
Cash Flow
Last updated:
Cash flow statement presents a set of outflows and inflows of cash within a company through operating, investing and financing activities. Over the last year, operating activities of Praxis Precision Medicines generated cash of -$111,136,000, which is more than the previous year. Cash used in financing activities reached the amount of $91,871,000 last year. Net change in cash is therefore $19,685,000.
Cash Flow
| 2018 | -20.72M | -63K | 37.80M |
|---|---|---|---|
| 2019 | -33.42M | -103K | 60.38M |
| 2020 | -52.62M | 4K | 304.41M |
| 2021 | -124.55M | -140.52M | 107.58M |
| 2022 | -185.04M | 96.88M | 10.46M |
| 2023 | -111.13M | 38.95M | 91.87M |
PRAX Cash Flow Statement (2018 – 2023)
| 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | |
|---|---|---|---|---|---|---|
Cash at beginning of period | 62.03M | 139.72M | 297.20M | 45.41M | 18.55M | 1.53M |
Operating activities | ||||||
Net income | -123.27M | -214.02M | -167.06M | -61.82M | -35.51M | -26.53M |
| Adjustments to reconcile net income to cash generated by operating activities: | ||||||
Depreciation and amortization | 432K | 419K | 182K | 50K | 37K | 1K |
Stock-based compensation expense | 24.85M | 28.59M | 22.69M | 5.21M | 668K | 0 |
| Deferred income tax benefit | 24.85M | 28.59M | 22.69M | 5.21M | 668K | 0 |
| Changes in operating assets and liabilities: | ||||||
Accounts receivable, net | 0 | 0 | 0 | 0 | 0 | 0 |
Inventories | 0 | 0 | 0 | 0 | 0 | 0 |
Accounts payable | -8.85M | 3.89M | 7.26M | 960K | -837K | 1.66M |
Cash generated by operating activities | -111.13M | -185.04M | -124.55M | -52.62M | -33.42M | -20.72M |
Investing activities | ||||||
Purchases Of Investments | 0 | -83.02M | -164.17M | 0 | 0 | 0 |
Investments In Property Plant And Equipment | -50K | -444K | -1.05M | 4K | -103K | -63K |
Acquisitions Net | 0 | -97.33M | 139.47M | 0 | 0 | 0 |
Cash generated by investing activities | 38.95M | 96.88M | -140.52M | 4K | -103K | -63K |
Financing activities | ||||||
Common Stock Issued | 91.59M | 9.56M | 107.58M | 334.41M | 60.38M | 0 |
Payments for dividends | 0 | 0 | 0 | 0 | 0 | 0 |
Repurchases of common stock | 0 | 0 | 0 | -30M | 0 | 0 |
Repayments of term debt | 0 | 0 | -763K | -696K | 0 | 0 |
Cash used in financing activities | 91.87M | 10.46M | 107.58M | 304.41M | 60.38M | 37.80M |
Net Change In Cash | 19.68M | -77.68M | -157.48M | 251.79M | 26.86M | 17.02M |
Cash at end of period | 81.71M | 62.03M | 139.72M | 297.20M | 45.41M | 18.55M |
| Data source | Data source | Data source | Data source |